It is worth noting that p16INK4A promoter methylation, analyzed by MSP, has been predominantly observed in 52% of NRAS-mutated metastatic melanomas but in only 7% of BRAF-mutated metastases [66]. Here, CDKN2A is linked to metastatic melanoma.